Health ❯ Healthcare

Clinical Trials

Phase 3 Trials Drug Development Drug Efficacy Patient Outcomes Phase III Trials Randomized Controlled Trials Research Studies Cancer Research Efficacy Studies Cancer Treatment

FDA Approves Oral Wegovy, First GLP-1 Pill for Obesity, With U.S. Launch in January

The once-daily semaglutide tablet showed mid‑teens weight loss in trials and is set to roll out with a $149 starter offer.

FDA Approves First Oral GLP-1 Weight-Loss Drug With Wegovy Pill Launching in January

AstraZeneca’s LATIFY Phase 3 Finds No Survival Benefit for Ceralasertib Plus Imfinzi in Pre-Treated NSCLC

Neurocrine’s Valbenazine Misses Phase 3 Goals in Dyskinetic Cerebral Palsy

FDA Approves Wegovy Weight-Loss Pill as First Oral GLP-1 for Obesity

Stories older than 24h

FDA Grants Accelerated Approval to Subcutaneous Lunsumio VELO for Relapsed Follicular Lymphoma

AstraZeneca Withdraws Andexxa From U.S. Market After FDA Says Risks Outweigh Benefits

Novo Nordisk Files FDA Application for Weekly CagriSema Obesity Shot as GLP-1 Competition Intensifies

Takeda’s AI-Assisted Psoriasis Pill Succeeds in Phase 3, Outperforms Otezla

Lilly Files Orforglipron Obesity Pill With FDA After Trial Shows Weight-Loss Maintenance

FDA Approves Rybrevant Faspro, a 5‑Minute Subcutaneous Amivantamab for EGFR‑Mutated Lung Cancer

Largest Blood-Test Study Finds Alzheimer’s Changes Common in Older Adults

Lilly’s Daily Obesity Pill Sustains Weight Loss After Switch From Wegovy or Zepbound

FDA Clears GSK’s Exdensur as First Twice-Yearly Add-On for Severe Eosinophilic Asthma

Lilly’s Triple-Agonist Retatrutide Shows Major Phase 3 Weight Loss as Grey-Market Use Prompts Warning

DBV Peanut Allergy Patch Succeeds in Pivotal Phase 3, Setting Up 2026 FDA Filing

FDA Clears Enhertu-Perjeta Combo for First-Line HER2-Positive Metastatic Breast Cancer

FDA Clears First New Oral Gonorrhea Antibiotics in Over 30 Years

FDA Expands Addyi Use to Postmenopausal Women, Including Those Over 65

Nektar’s Alopecia Drug Misses Phase 2b Goal as Company Cites Ineligible Patients, Plans Phase 3